永泰生物-B(06978)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

06978 永泰生物-B

交易中 06-09 13:43:23

0.610

-0.060

-8.96%

最高0.670	最低0.600	成交量67.40万
今开0.670	昨收0.670	日振幅10.45%
总市值3.77亿	流通市值3.77亿	总股本6.18亿
成交额41.51万	换手率0.11%	流通股本6.18亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"06978","market":"HK","secType":"STK","nameCN":"永泰生物-B","latestPrice":0.61,"timestamp":1780983479381,"preClose":0.67,"halted":0,"volume":674002,"delay":0,"changeRate":-0.08955223880597023,"floatShares":618000000,"shares":618000000,"eps":-0.4856892782422679,"marketStatus":"交易中","change":-0.06,"latestTime":"06-09 13:43:23","open":0.67,"high":0.67,"low":0.6,"amount":415051,"amplitude":0.104478,"askPrice":0.61,"askSize":1000,"bidPrice":0.6,"bidSize":70000,"shortable":0,"etf":0,"ttmEps":-0.47875085998166406,"tradingStatus":2,"nextMarketStatus":{"tag":"收盘","tradingStatus":0,"beginTime":1780992600000},"marketStatusCode":2,"adr":0,"listingDate":1594310400000,"exchange":"SEHK","adjPreClose":0.67,"openAndCloseTimeList":[[1780968600000,1780977600000],[1780981200000,1780992000000]],"volumeRatio":3.084613,"lotSize":1000,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/06978","defaultTab":"news","newsList":[{"id":"2642971458","title":"京新药业：目前中药创新药在公司管线中并非主要产品","url":"https://stock-news.laohu8.com/highlight/detail?id=2642971458","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2642971458?lang=zh_cn&edition=full","pubTime":"2026-06-09 08:48","pubTimestamp":1780966092,"startTime":"0","endTime":"0","summary":"证券之星消息，京新药业(002020)06月09日在投资者关系平台上答复投资者关心的问题。投资者提问：贵公司未来有考虑进军中药创新药的行列吗？我认为贵公司是好公司，至少不会虚无缥缈得和投资者讲故事，是愿意实打实的做好企业的发展，希望以后原研工作，从研发、审批、销售中都有好产品担当，打造良好的产品产业梯队体系，谢谢京新药业回复：您好！目前中药创新药在公司管线中并非主要产品。谢谢您对公司的关注和认可，公司会踏实做好经营工作，积极推进创新转型。谢谢！本文数据来源于深圳证券交易所互动易，仅供参考不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026060900006078.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK1574","BK1161","159992","002020","06978"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2641879934","title":"博济医药(300404.SZ)拟定增募资不超4.47亿元 用于中药创新药研发项目等","url":"https://stock-news.laohu8.com/highlight/detail?id=2641879934","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2641879934?lang=zh_cn&edition=full","pubTime":"2026-06-08 21:46","pubTimestamp":1780926415,"startTime":"0","endTime":"0","summary":"智通财经APP讯，博济医药(300404.SZ)发布公告，公司拟向不超过35名符合中国证监会规定条件的特定投资者发行A股股票，发行募集资金总额不超过4.47亿元，扣除发行费用后拟将全部用于：药物评价中心扩建升级项目、中药创新药研发项目、医药研发大数据智能一体化平台项目、SMO中心建设项目、补充流动资金。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1451676.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["06978","BK1161","BK0216","159992","BK1574","300404"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2641104810","title":"6月8日津药药业（600488）涨停分析：创新药政策催化、研发布局深化驱动","url":"https://stock-news.laohu8.com/highlight/detail?id=2641104810","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2641104810?lang=zh_cn&edition=full","pubTime":"2026-06-08 15:31","pubTimestamp":1780903883,"startTime":"0","endTime":"0","summary":"证券之星消息，津药药业6月8日涨停收盘，收盘价5.69元。该股于9点39分涨停，1次打开涨停，截止收盘封单资金为6818.27万元，占其流通市值1.1%。6月8日的资金流向数据方面，主力资金净流入2.27亿元，占总成交额43.53%，游资资金净流出9069.34万元，占总成交额17.36%，散户资金净流出1.37亿元，占总成交额26.17%。近5日资金流向一览见下表：该股为数字经济，化学原料药，医药概念热股。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026060800014716.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0102","BK0012","BK1161","BK1574","600488","06978","159992","BK0028","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2641101540","title":"港股异动 | 创新药概念股全线承压 流动性收紧直接压制板块估值 机构指BINSA草案影响偏情绪","url":"https://stock-news.laohu8.com/highlight/detail?id=2641101540","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2641101540?lang=zh_cn&edition=full","pubTime":"2026-06-08 15:08","pubTimestamp":1780902518,"startTime":"0","endTime":"0","summary":"消息面上，中东紧张局势推高能源价格之际，劳动力市场表现强劲，强化了市场对美联储年内加息的押注。国海证券此前在风险提示中指出，若全球及国内宏观货币政策节奏不及预期，将直接影响医药板块的估值水平与投融资环境。创新药、CXO等成长赛道对流动性较为敏感，若美联储降息周期延后，或国内降准降息落地不及预期，市场流动性收紧将直接压制成长赛道估值。此外，6月2日，美国《生物技术投资国家安全法》法案公布。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1451312.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU1226287792.SGD","BK1574","IE00B5MMRT66.SGD","LU0501845795.SGD","LU1960683339.HKD","VXUS","159992","LU2039709279.SGD","LU1008478684.HKD","LU2488822045.USD","01801","LU0072913022.USD","LU2097828714.EUR","BK4588","BK4585","LU1152091168.USD","01093","IE0008369823.USD","01177","LU1993786604.SGD","IE00B543WZ88.USD","LU1969619763.USD","SG9999004220.SGD","LU1328277881.USD","HK0000165453.HKD","06978","BK1593","01530","LU0140636845.USD","LU2097828631.EUR","LU0314109678.HKD","LU0455707207.USD","BK1515","BK1583","LU0502904849.HKD","LU2242644610.SGD","BK1191","LU1226288253.USD","LU2097828557.USD","LU1813983027.USD","BK1161","IE00BZ08YT58.USD","LU0880133367.SGD","IE00B031HY20.USD","LU1226287875.USD","LU1951186391.HKD","BK1589","LU1226288170.HKD","LU2328871848.SGD","LU0067412154.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2641109868","title":"港股通创新药6连跌，520880再创新低！标的指数本轮调整跌幅超37%","url":"https://stock-news.laohu8.com/highlight/detail?id=2641109868","media":"新浪基金","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2641109868?lang=zh_cn&edition=full","pubTime":"2026-06-08 14:27","pubTimestamp":1780900020,"startTime":"0","endTime":"0","summary":"6月8日午后，A股港股跌势进一步扩大，沪指、恒指跌逾1.5%，AH创新药资产继续下行。重仓A股创新药的药ETF华宝、满仓港药的港股通创新药ETF华宝场内价格双双刷新历史低点。100%创新药研发标的——港股通创新药ETF华宝跌超3%，为连续第6日下跌。　　据统计，截至上个交易日，港股通创新药ETF华宝标的指数本轮调整区间跌幅已超过37%，区间年化波动率超33%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/money/fund/etf/2026-06-08/doc-iniasscn8696208.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK4588","BK1574","520880","VXUS","159992","BK1161","06978","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2641177986","title":"东方证券：国产创新药开启NSCLC一线治疗范式革新","url":"https://stock-news.laohu8.com/highlight/detail?id=2641177986","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2641177986?lang=zh_cn&edition=full","pubTime":"2026-06-08 09:55","pubTimestamp":1780883706,"startTime":"0","endTime":"0","summary":"东方证券主要观点如下：一代PD-1单药±化疗标准松动，NSCLC一线进入二代IO、ADC+IO双线迭代周期本届ASCO大会上，来自国产创新药的三项重磅临床数据表明，NSCLC一线金标准，即传统的PD-1±化疗的正迎来系统性替代。在免疫1.0时代，国产创新药大多跟随海外PD-1药物的研发，如今快速发展至引领免疫2.0时代，有望创造肺癌千亿市场治疗范式的全面革新。该研究是全球首个ADC+IO一线NSCLC取得III期阳性结果，有望改写PD-L1阳性NSCLC一线用药格局。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1451213.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1574","IE00B5MMRT66.SGD","LU0348767384.USD","159992","LU2476274720.SGD","LU2488822045.USD","LU2778985437.USD","01801","LU0540923850.HKD","LU0348827113.USD","LU2097828714.EUR","BK0012","LU2476274308.USD","LU0561508036.HKD","LU0348766576.USD","LU0348735423.USD","LU0417516738.SGD","LU1720050803.USD","IE00B543WZ88.USD","LU0417516571.SGD","LU1794554557.SGD","LU1969619763.USD","03958","HK0000165453.HKD","06978","LU2097828631.EUR","06990","LU0348825331.USD","LU2097828474.EUR","IE00BPRC5H50.USD","LU0417516902.SGD","BK0276","LU0455707207.USD","BK1147","BK1564","LU0348783233.USD","BK0183","LU0502904849.HKD","LU2097828805.USD","600958","LU2097828557.USD","BK0028","LU0348784397.USD","BK1161","LU0196878994.USD","LU0634319403.HKD","LU1961090484.USD","BK1589","09926","LU2328871848.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2641175222","title":"恐慌过度还是“黄金坑”？三大逻辑支撑创新药底部布局，杠杆资金已进场","url":"https://stock-news.laohu8.com/highlight/detail?id=2641175222","media":"新浪基金","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2641175222?lang=zh_cn&edition=full","pubTime":"2026-06-07 19:27","pubTimestamp":1780831620,"startTime":"0","endTime":"0","summary":"6月5日，A股港股市场均延续调整，沪指跌0.74%报4027.74点，创指重挫3.2%，恒指跌1.15%三连阴。医药资产韧性凸显，尽管冲高回落，整体表现显著好于大市。其资金面近期逆向升温，截至6月4日，512170近10日累获12.66亿元增仓。　　值得关注的是，近期港股通创新药加速筑底，杠杆资金开始进场。截至6月4日，港股通创新药ETF华宝融资余额达1.05亿元，创历史新高。仅2026年第一季度，国产创新药出海交易总额已超过600亿美元。","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/money/fund/etf/2026-06-07/doc-iniaqtnk9521435.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["AAAU","QOmain","PHYS","BTGD","GCmain","GDXY","IAUI","DGP","FGDL","IAUM","1OZmain","UYM","GLDM","DZZ","BAR","JDST","PALL","PICK","SGDM","DBC","GOLY","GBUG","MGCmain","DUST","GDXJ","GLD","SGCmain","UGL","RING","159831","JNUG","IAU","GLL","USG","XME","DULL","SGOL","159992","06978","SGUmain","GDXD","CEF","GDX","BEGS","SHNY","GLTR","GOAU","159934","OUNZ","GDXU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2641148362","title":"康方新药取得历史性突破，为何蒸发百亿市值","url":"https://stock-news.laohu8.com/highlight/detail?id=2641148362","media":"经济观察网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2641148362?lang=zh_cn&edition=full","pubTime":"2026-06-05 19:42","pubTimestamp":1780659720,"startTime":"0","endTime":"0","summary":"6月1日，康方生物开盘后一度涨超12%，然而高开低走，此后三日连续下跌，截至6月5日收盘，康方生物总市值862亿港元，数日内市值跌去超百亿。在康方生物的叙述中，这份登陆ASCO全体会议的临床数据堪称历史性突破。无可辩驳的是，康方生物的HARMONi-6已达到全部预期终点，取得显著阳性。股价为何下跌数据公布后3日，康方生物的市值跌去超百亿港元，截至发稿，总市值已不足千亿。","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/roll/2026-06-05/doc-iniakfhq8388122.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/roll/2026-06-05/doc-iniakfhq8388122.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["LU2399975544.HKD","LU0634319403.HKD","LU0540923850.HKD","LU0348767384.USD","LU2476274720.SGD","LU0417516738.SGD","BK4203","09926","IE00BPRC5H50.USD","IE00B5MMRT66.SGD","LU0348766576.USD","LU2476274308.USD","LU1720050803.USD","02616","LU0417516902.SGD","PFS","LU0348783233.USD","LU0348735423.USD","BK4225","BK1574","LU2488822045.USD","BK1161","06978","HR","LU0348784397.USD","IE00B543WZ88.USD","LU0561508036.HKD","LU1794554557.SGD","BK4195","LU0417516571.SGD","LU0348827113.USD","LU0348825331.USD","LU1961090484.USD","BK4211","LU2778985437.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2641117001","title":"贝达药业：正在积极推进自主创新药海外权益的转让工作","url":"https://stock-news.laohu8.com/highlight/detail?id=2641117001","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2641117001?lang=zh_cn&edition=full","pubTime":"2026-06-05 18:00","pubTimestamp":1780653639,"startTime":"0","endTime":"0","summary":"证券之星消息，贝达药业(300558)06月05日在投资者关系平台上答复投资者关心的问题。投资者提问：海思科都有30亿bd合作，你们的到底在哪里？贝达药业回复：您好！BD交易需要匹配合适的合作伙伴、合理的估值和有利的交易条件，公司高度关注BD合作机会，正在积极推进自主创新药海外权益的转让工作。目前，公司研发管线中BPI-572270、BPI-585725等项目均具有全球化合作的潜力，公司将积极对接意向第三方，在充分评估项目价值和市场时机的基础上，审慎推进对外授权合作。如有重大合作进展，公司会及时公告披露。谢谢！本文数据来源于深圳证券交易所互动易，仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026060500031266.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["06978","BK0239","BK1574","BK0060","300558","159992","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1152093512","title":"港股创新药概念股普涨，康诺亚-B、科伦博泰生物涨超5%","url":"https://stock-news.laohu8.com/highlight/detail?id=1152093512","media":"老虎资讯综合","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1152093512?lang=zh_cn&edition=full","pubTime":"2026-06-05 09:54","pubTimestamp":1780624485,"startTime":"0","endTime":"0","summary":"6月5日，港股创新药概念股普涨，$康诺亚-B(02162)$、$科伦博泰生物(06990)$涨超5%，$恒瑞医药(01276)$、$信达生物(01801)$涨超4%，$药明康德(02359)$、$歌礼制药-B(01672)$涨超3%。","market":"hk","thumbnail":"https://static.tigerbbs.com/fd680cd945fd32917c8ece66ec685e5f","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/fd680cd945fd32917c8ece66ec685e5f"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"df6be86a5967f2b571d48b8ac559bb5d","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02162","BK4585","BK1161","BK1587","VXUS","06978","BK1583","BK1574","06990","BK4588","LU0196878994.USD","159992"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2641519528","title":"创新药命门何解？","url":"https://stock-news.laohu8.com/highlight/detail?id=2641519528","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2641519528?lang=zh_cn&edition=full","pubTime":"2026-06-05 09:00","pubTimestamp":1780621206,"startTime":"0","endTime":"0","summary":"内循环必须转起来","market":"sg","thumbnail":"https://img3.gelonghui.com/43c9f-4bc5e9f9-ce48-4aa4-ac45-032a71ef3e2b.jpg?guru_height=855&guru_width=1280&guru_size=58471","type":0,"news_type":0,"thumbnails":["https://img3.gelonghui.com/43c9f-4bc5e9f9-ce48-4aa4-ac45-032a71ef3e2b.jpg?guru_height=855&guru_width=1280&guru_size=58471"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/p/5067406","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"gelonghui_highlight","symbols":["BK1574","06978","BK1161","159992"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640182158","title":"一品红(300723.SZ)子公司创新药APH04935片获得临床试验注册申请受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2640182158","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2640182158?lang=zh_cn&edition=full","pubTime":"2026-06-04 16:12","pubTimestamp":1780560741,"startTime":"0","endTime":"0","summary":"智通财经APP讯，一品红(300723.SZ)发布公告，近日，公司全资子公司广州一品红制药有限公司自主研发的创新药物APH04935片的药物临床试验申请获得国家药品监督管理局受理，并收到《受理通知书》。APH04935片是由公司自主研发的一种高活性、高选择性的小分子GLP-1R激动剂，目标成为一款一天给药一次的口服小分子GLP-1R激动剂，拟用于成人超重或肥胖患者的体重减轻及长期减重管理。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1450086.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","159992","06978","300723","BK0239","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640188674","title":"永泰生物-B(06978)：ATL 开启商业化 EAL谋划重新申报","url":"https://stock-news.laohu8.com/highlight/detail?id=2640188674","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2640188674?lang=zh_cn&edition=full","pubTime":"2026-06-03 22:55","pubTimestamp":1780498537,"startTime":"0","endTime":"0","summary":"集团于2025年9月已获海南省乐城医疗药品监管局附条件批准，可于海南博鳌乐城国际医疗旅游先行区开展ATL用于预防肝癌术后复发的临床转化应用，并且已于2026年4月启动商业化过程。集团亦已于2026年4月获得ATL在北戴河生命健康产业创新示范区的临床使用批准，预计将于2026年6月开始商业化。于本公告日期，已有两名患者接受ATL疗法，并已完成三次ATL回输。公司预期将自ATL商业化获取收益，并将继续宣传及推进ATL转化应用。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1449867.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","BK1574","06978"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1147108269","title":"永泰生物-B 于2025年9月获海南ATL临床转化应用附条件批准","url":"https://stock-news.laohu8.com/highlight/detail?id=1147108269","media":"美股速递","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1147108269?lang=zh_cn&edition=full","pubTime":"2026-06-03 22:54","pubTimestamp":1780498459,"startTime":"0","endTime":"0","summary":"永泰生物-B 宣布，其于2025年9月获得了在海南进行ATL临床转化应用的附条件批准。这一进展标志着公司在特定治疗领域的研发向前迈出了关键一步，为其相关技术或产品在特定区域的临床推进奠定了基础。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06978","BK1574","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640904000","title":"楚天科技：中国创新药重磅交易金额高达193亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2640904000","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2640904000?lang=zh_cn&edition=full","pubTime":"2026-06-03 20:52","pubTimestamp":1780491131,"startTime":"0","endTime":"0","summary":"证券之星消息，楚天科技06月02日在投资者关系平台上答复投资者关心的问题。根据长江证券投资策略报告，近年来，中国创新药BD交易的数量与金额多次刷新纪录。2025年，中国创新药重磅交易金额高达193亿美元，占全球重磅交易金额的比例达20%，这表明中国创新药日益受到国际资本和跨国制药企业的青睐，出海的产业趋势有望延续。中国制药装备的领军企业，近年来产品品质不断提升，已达到或接近国际先进水平。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026060300044416.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["06978","BK0251","159992","BK0077","BK1574","BK0061","BK1161","300358","BK0028"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640722199","title":"ST诺泰：已与Incyte、Gilead等知名创新药企建立稳固合作关系","url":"https://stock-news.laohu8.com/highlight/detail?id=2640722199","media":"证券之星","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2640722199?lang=zh_cn&edition=full","pubTime":"2026-06-03 16:27","pubTimestamp":1780475250,"startTime":"0","endTime":"0","summary":"证券之星消息，ST诺泰(688076)06月03日在投资者关系平台上答复投资者关心的问题。投资者提问：董秘你好 近日看到信达与辉瑞签订超100亿美元的肿瘤药物研发合同，我想请问诺泰生物何时能具备与国际大厂签订药物研发计划的能力？ST诺泰回复：尊敬的投资者您好，公司已与Incyte、Gilead等知名创新药企建立了稳固的合作关系，公司会在定期报告中披露已签署重要订单情况。此外，公司如签订达到《上海证券交易所科创板股票上市规则》中规定的重大合同披露标准的订单合同，会及时履行信息披露义务，感谢您的关注！本文数据来源于上海证券交易所e互动，仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026060300033187.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688076","BK1574","BK0239","159992","06978","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640974503","title":"股价3日重挫40%，创新药明星公司突传利空","url":"https://stock-news.laohu8.com/highlight/detail?id=2640974503","media":"21世纪经济报道","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2640974503?lang=zh_cn&edition=full","pubTime":"2026-06-03 15:23","pubTimestamp":1780471380,"startTime":"0","endTime":"0","summary":"　　继6月1日股价暴跌超32%后，今日，港股基石药业继续下跌，截至发稿股价跌3.78%，股价最近3日累计跌40%。　　事实上，早在2026年4月发布2025年度业绩报告时，基石药业便提前释放管线进展信号。2025年10月，基石药业便首次披露了CS2009的I期临床研究数据。　　对于长达半年多的显著调整，平安医疗健康基金经理周思聪向媒体表示，创新药板块这一轮调整并非行业基本面恶化所致，而是板块发展过程中的正常出清。","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/wm/2026-06-03/doc-iniachns4222157.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/wm/2026-06-03/doc-iniachns4222157.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK1161","BK1574","159992","06978"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640730699","title":"ASCO彩蛋频出，能否拯救港股创新药企估值？","url":"https://stock-news.laohu8.com/highlight/detail?id=2640730699","media":"21世纪经济报道","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2640730699?lang=zh_cn&edition=full","pubTime":"2026-06-03 12:30","pubTimestamp":1780461012,"startTime":"0","endTime":"0","summary":"21世纪经济报道记者唐唯珂国产创新药持续乘风破浪，彩蛋频出，但港股创新药企估值却并不亮眼。美国临床肿瘤学会（ASCO）年会是全球肿瘤学领域规模最大、最具影响力的学术会议之一，全美乃至全球最有影响力的肿瘤临床医生和研究者都会悉数到场，投资人、媒体和患者组织共同参与。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202606033758784044.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202606033758784044.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK4585","06978","BK1161","BK1574","VXUS","BK4588","159992"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640673927","title":"创新药研发及商业化加速 复星国际(00656)“最强估值锚点”夯实确定性","url":"https://stock-news.laohu8.com/highlight/detail?id=2640673927","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2640673927?lang=zh_cn&edition=full","pubTime":"2026-06-03 09:30","pubTimestamp":1780450200,"startTime":"0","endTime":"0","summary":"创新药步入收获期，全球市场商业潜力加速兑现近年来，在创新及全球化两大引擎的推动下，复星的创新药持续在全球市场商业放量，成为其重要的增长极。随着复星创新药进入商业化放量周期，其利润贡献和估值支撑能力都在明显增强。其中，花旗着重指出，基于向好的基本面情况，预计复星国际2026年业绩表现强劲。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1449419.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02196","BK1515","BK1593","BK1574","BK1230","00656","06978","159992","BK1161","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640919994","title":"九洲药业：公司CDMO业务主要致力于向全球客户提供创新药临床前CMC，临床I、II、III期，NDA至全球上市全产业链的一站式优质服务","url":"https://stock-news.laohu8.com/highlight/detail?id=2640919994","media":"证券之星","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2640919994?lang=zh_cn&edition=full","pubTime":"2026-06-02 17:19","pubTimestamp":1780391947,"startTime":"0","endTime":"0","summary":"证券之星消息，九洲药业(603456)06月02日在投资者关系平台上答复投资者关心的问题。投资者提问：董秘你好，请问贵司是否属于能承接后端订单、复杂新分子和全球临床需求的公司呢？九洲药业回复：您好，感谢您对公司的关注与支持，公司CDMO业务主要致力于向全球客户提供创新药临床前CMC，临床I、II、III期，NDA至全球上市全产业链的一站式优质服务，谢谢！本文数据来源于上海证券交易所e互动，仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026060200032885.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK1161","603456","BK1574","06978","BK0070","159992"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.eaal.net","stockEarnings":[{"period":"1week","weight":-0.0694},{"period":"1month","weight":-0.2299},{"period":"3month","weight":-0.7265},{"period":"6month","weight":-0.7657},{"period":"1year","weight":-0.788},{"period":"ytd","weight":-0.7713}],"compareEarnings":[{"period":"1week","weight":-0.0292},{"period":"1month","weight":-0.0658},{"period":"3month","weight":-0.0502},{"period":"6month","weight":-0.0346},{"period":"1year","weight":0.0363},{"period":"ytd","weight":-0.038}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"永泰生物制药有限公司是一家主要从事用于治疗癌症的细胞免疫产品的研发、制造及商业化的投资控股公司。该公司的非转基因细胞产品管线包括扩增活化淋巴细胞（EAL）和6B11-OCIK注射液。该公司的嵌合抗原受体T（CAR-T）细胞产品管线包括CAR-T-19注射液、迪诺仑赛注射液和aT19注射液。该公司的T细胞受体工程化T细胞疗法（TCR-T）细胞产品管线包括YT003、YT008及YT007。该公司主要在中国市场开展业务。","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":-0.074078},{"month":2,"riseRate":0.666667,"avgChangeRate":0.181642},{"month":3,"riseRate":0.333333,"avgChangeRate":-0.080929},{"month":4,"riseRate":0.166667,"avgChangeRate":-0.167652},{"month":5,"riseRate":0.333333,"avgChangeRate":-0.073624},{"month":6,"riseRate":0.666667,"avgChangeRate":0.043771},{"month":7,"riseRate":0.2,"avgChangeRate":-0.000149},{"month":8,"riseRate":0.5,"avgChangeRate":0.012587},{"month":9,"riseRate":0.166667,"avgChangeRate":-0.035807},{"month":10,"riseRate":0.5,"avgChangeRate":-0.057833},{"month":11,"riseRate":0.5,"avgChangeRate":0.001253},{"month":12,"riseRate":0.666667,"avgChangeRate":0.067669}],"exchange":"SEHK","name":"永泰生物-B","nameEN":"IMMUNOTECH-B"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.43.1","shortVersion":"4.43.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"永泰生物-B(06978)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供永泰生物-B(06978)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"永泰生物-B,06978,永泰生物-B股票,永泰生物-B股票老虎,永泰生物-B股票老虎国际,永泰生物-B行情,永泰生物-B股票行情,永泰生物-B股价,永泰生物-B股市,永泰生物-B股票价格,永泰生物-B股票交易,永泰生物-B股票购买,永泰生物-B股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"永泰生物-B(06978)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供永泰生物-B(06978)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}